New Zealand markets open in 8 hours 5 minutes

Cingulate Inc. (CING)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.9213+0.0008 (+0.09%)
As of 09:51AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close0.9205
Open0.9100
Bid0.6771 x 200
Ask1.2700 x 200
Day's range0.9100 - 0.9240
52-week range0.9100 - 23.8000
Volume6,753
Avg. volume316,606
Market cap4.616M
Beta (5Y monthly)-0.96
PE ratio (TTM)N/A
EPS (TTM)-26.0000
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est21.50
  • GlobeNewswire

    Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update

    $17.8 Million Raised Since Beginning of 2023$9.1 Million of Debt Converted to Equity at a PremiumPhase 3 ADHD Data Continues to Impress KANSAS CITY, Kan., April 01, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the twelve months ended December 31, 2023

  • GlobeNewswire

    Cingulate to Participate in Benzinga All Live Access Event

    KANSAS CITY, Kan., March 19, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Chairman and CEO Shane J. Schaffer will participate in a live Benzinga All Access event on Friday March 22, 2024, at 12 p.m. ET. The discussion will focus on Cingulate’s pipeline and product portfol

  • GlobeNewswire

    Cingulate to Attend DCAT Week 2024 in New York City

    Will Host Licensing Meetings with Multiple Parties to Discuss Assets, Pipeline and TechnologyKANSAS CITY, Kan., March 06, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced today that it will be attending DCAT Week (Drug, Chemical & Associated Technologies Association) March 18-21, 2024,